Annual Report - · PDF filewhich will be completed in the course of next year. ... but also...
34
Annual Report
Transcript of Annual Report - · PDF filewhich will be completed in the course of next year. ... but also...
Annual Report
| 3
Is anyone ill or on holiday?He can be found at the head office every day..
Tim is always prepared to stand in.
Tim van Velsen (volunteer)
Table of Contents
Foreword 4
Donating Blood 10
Personnel & Organization 18
Products & Services 26
Research 32
Report from the Executive Board 42
Report from the Supervisory Board 48
Financial Results and 53Financial Position
Auditor’s Report 58
Annex 60(Other positions held by Members of the
Supervisory Board and the Executive Board)
All employees in the photographs in this annual report achieved something extraordinary in 2010 and were recommended by colleagues.
4 | | 5
How would you characterize the year 2010?‘As a year in which the Sanquin Blood Supply Foundation
has taken some major steps with respect to a number
of new developments. You could even call it a wave of
innovation. In this context, I have in mind the new
building for the Plasma Products and Research Divisions,
which will be completed in the course of next year. But
also the preparations for a stem cell laboratory, where the
innovative stem cell therapies will be developed this year.
In addition, at the end of 2010 the decision was taken to
introduce a software package to support quality assurance
with system reports for the entire Sanquin organization.’
What kind of year was it for the donors?` ‘In 2010, a new donor participation structure was
introduced. We value a structure that enables donors to
express their views effectively. Together with consultancy
firm Twijnstra Gudde, we carefully looked at how we can
optimally implement this structure. The new National
Donor Council now has four seats for new, independent
parties, such as donor associations. This makes donor
contribution more transparent. We expect donors to feel
better represented as a result.
Another new development for donors is that we are going
to introduce an additional test in the screening of donors
in 2011, the so called Anti-Hepatitis B core test. This test
detects antibodies against the nucleus of the hepatitis B
virus. In this way we want to eliminate risks as much
as possible and give more certainty to the recipients of
blood products.’
Moving forward
Innovation, investments, responding to unexpected situations in a flexible manner: Theo Buunen, chairman of the Executive Board, looks back on the highlights of the past year.
Foreword
‘We have proved again that we are able to respond to unexpected situations in a flexible manner’
Foreword
6 | | 7
the RhD determination as early as the 27th weekTogether with her colleagues, she managed to offer
of pregnancy in a fully automated manner.
Aicha ait Soussan (senior analyst)
What else are you proud of, looking at the past year?‘An important issue in the past year was the Q fever
outbreak. An epidemic seemed a realistic scenario. We
introduced a new test for donors to rule out that they were
infected with the Q fever bacterium. Not only did we spend
a lot of energy in developing and tuning this test, but the
logistics of introducing the test for the areas at risk was
quite a job. But things went smoothly and I’m very proud
of that. It turns out once again that we are able to respond
to unexpected situations in a flexible manner. When it
comes to flexibility: the unexpected growth in the produc-
tion of the medicine Cinryze™ also made heavy demands
on the flexibility of our staff in the production line over the
past year. All honour to them as well.’
What issues deserve extra attention next year?‘Next year, we will see how some changes we have
initiated will turn out in practice. Such as the Quartslag
Operation, by which the four blood banks from the four
regions are incorporated into a single Blood Bank division.
This change has had drastic consequences for the original
division management. Management is now vested in
four unit directors at national level, based on the various
processes: Production, Quality, Donor Affairs and Medical
Affairs. I am confident that this other structure will have a
beneficial effect on the uniformity, efficiency and improve-
ment of quality and, hence, on the services to donors and
our customers.’
Last but not least?‘At this point, I would like to say a few words about the
retirement of our board member Prof. Ernest Briët. Ernest
has been very important to Sanquin, because of his signifi-
cant contribution to the translation of research results into
the practice of blood transfusion for example. Fortunately,
we have found a worthy successor in the person of Prof.
René A. W. van Lier. Before he started at the AMC to
become Professor of Experimental Immunology in 2000,
he had worked as a doctor at Sanquin for more than 16
years. In recent years, René has been establishing quite
a few bridges between the hospital and Sanquin. We are
therefore very happy that he is back with us.’
8 | | 9
they drive it from east to west, to the than a Mobile Blood Collection Unit of 68m2 −
As sovereigns − as if it concerns a Fiat 500 rather
great delight of all donors in the province of Zeeland.
Gerald Eikholt (l), Farouk Habib (m) (drivers, Mobile Blood Collection Unit), Erik Oostveen (r) transport team leader
10 | | 11
In June of last year, the project leader at Sanquin
proudly presented the International Donor Management
Handbook, a practical guide that compiles knowledge,
experience and good practices.
In the middle of last year, the time had come: at the
congress of the International Society for Blood Transfusion
(ISBT), the Donor Management Handbook was presented.
Sanquin was project leader of the large-scale European
project called DOMAINE (DOnorMAnagement IN Europe),
which was co-financed by the European Union. ‘The
immediate cause was the need for a practical hand-
book which combines knowledge, experiences and
good practices in the field of donor management’,
says manager Donor Studies Wim de Kort. ‘We, and
our Belgian colleagues, were frequently asked all
kinds of questions: how do you actually organize the
blood supply, why does it run so smoothly in your
country? The large-scale exchange of knowledge could
be improved.’ In 2007 Sanquin started talks with
some members of the interest group called the European
Blood Alliance for the first time. This past year the
Handbook was finished. Wim: ‘And we are really very
proud of that.’
SafetyThe DOMAINE project consisted of three stages. In the
first stage, a large-scale investigation was conducted into
the good elements of all European blood banks. Some
of the topics were the following: what are better ways of
attracting and keeping donors? How do you organize
the collection of blood? How do you guarantee safety for
donors? These results formed the basis for the handbook.
Writing it constituted the second stage. In 2010 the hand-
book was finished and it was made available to the public
on the Internet. Blood banks may use it in setting up and
developing their own organization. Wim: ‘All aspects of
donor management are addressed in clearly arranged
chapters from a very practical angle. It includes tips
and tools, but also descriptions of logistic processes and
the consideration of ethical issues.’
In addition to an English version, Dutch, French, Portu-
guese and Spanish translations are now being prepared.
Recently, the third stage of the DOMAINE project was
launched: setting up a two-day interactive training
programme for the purpose of using the handbook in
the best possible manner. Wim: ‘From file management
to marketing techniques, from medical issues to the
organization of a blood collection: all aspects of donor
management are addressed.’ The first training session
will be held in June 2011, during the annual ISBT congress
in Portugal. See also www.domaine-europe.eu
All in the HandbookDonating Blood
‘From file management to marketing techniques, from medical affairs to the organization of blood collection: all aspects of donor management are addressed.’
Donating Blood
12 | | 13
Every day they take care of fresh coffee,crunchy croquettes and spotlessly clean meeting rooms.
An Kooistra (l), Despina Tsaklidou (m) and Alice Fennema (r) (catering team in Rotterdam)
Key figures of the Dutch blood supply (situation in the year 2010)
2010 2009
Donor base
Number of registered donors 406,127 404,184
Number of recorded donors* 395,226 393,811
Donation frequency of whole blood donors per year 1.63 1.70
Donation frequency of plasmapheresis donors per year 5.53 5.34
Number of donors per 1,000 inhabitants 24.40 23.70
Number of donations
Total number of donations 883,346 906,767
Number of whole blood donations 542,160 575,050
Number of apheresis donations 341,186 331,717
Use
Use of red blood cell concentrates 548,105 564,290
Number of platelets (from whole blood in donor units) 281,476 246,768
Number of units of fresh frozen plasma 81,742 90,390
Kilo of plasma in total (incl. of apheresis) supplied to Plasma Products division 348,369 342,995
*Excluding donors who are registered, but have not yet donated blood
Proportion of donors and supply of red blood cells
Whole blood donors 333,439 331,738
Erythrocytes supplied 548,105 564,290
In recent years, the use of erythrocytes in hospitals has dropped sharply. Together with the hospitals we managed to improve the
level of care and realize a smaller number of transfusions. More than ever before, transfusions are life-saving. Sanquin has adjusted
the number of donations in line with this trend and calls donors only if necessary. During processing, whole blood donations are
separated into various components. Therefore the figures concerning use may be higher than the number of donations.
Donating Blood
14 | | 15
Further, in 2010 a selected proportion of the blood donations were screened as a precautionary measure for the presence of
Coxiella burnetii DNA (Q fever). This screening was carried out in the period from 15 March to 1 November 2010 on donors living
in areas with the highest infection rates for Q fever. In total, 6,830 donations were individually tested. Coxiella burnetii DNA was
not found in any of these donations.
Whole-blood donors per blood group 2010
Blood group North East South East South West North West Sanquin In % Compared to 2009 (=100)
0+ 29,589 30,003 31,217 32,232 123,041 36.90% 122,898 100
0- 9,838 8,828 9,632 10,023 38,321 11.49% 38,758 99
A+ 25,762 26,263 26,309 27,637 105,971 31.78% 104,516 101
A- 6,134 6,152 6,389 6,886 25,561 7.67% 25,401 101
B+ 5,379 5,693 6,495 6,018 23,585 7.07% 23,353 101
B- 1,332 1,337 1,607 1,464 5,740 1.72% 5,754 100
AB+ 1,892 2,158 2,555 2,316 8,921 2.68% 8,746 102
AB- 573 535 577 614 2,299 0.69% 2,312 99
Total 80,499 80,969 84,781 87,190 333,439 100.00% 331,738 101
Percentage 0 negative in population, donors and red blood cells supplied
In population 7.65%
Among Donors 11.49%
Red blood cells supplied 13.50%
Whole blood logistics(in donor units)
Whole blood donations 542,160
Red blood cells to hospital 548,105
Hepatitis B Virus
HIV-1/2
HTLV-I/II
Lues
Hepatitis C virus
Overview of the number of donors with a positive result on screening for infectious diseases Every donation is tested. In general, infections are more frequently found in donors who donate blood for the first time.
Of course, blood products containing infectious pathogens are destroyed.
Donating Blood
0
10
20
30
40
50
60
70
80
90
20062005 2007 2008 2009 2010
0
2
4
6
8
10
12
20062005 2007 2008 2009 2010
0
1
2
3
4
20062005 2007 2008 2009 2010
0
10
20
30
40
50
60
20062005 2007 2008 2009 2010
0
5
10
15
20
25
30
35
20062005 2007 2008 2009 2010
Number of first time donors
First time donors per 100,000
Number of repeat donors
Repeat donors per 100,000
Marian Nordbeck-Vos en Rasida Joelfan
(distribution assistant and export assistant)
When their colleague at the export department suddenly left,
the two of them immediately put their backs into the task at hand.
16 | | 17
At a distance of 200 km from each other, they organize everything,down to the smallest detail, for their joint donor manager;
one of them in Nijmegen, the other in Groningen.
Barbara Hatzopoulos (l) and Antje Stoepker (r) (management assistants)
18 | | 19
‘Of course, we would have liked to achieve this 7.1
of the benchmark,’ says Rob Lijten, personnel and organi-
zation manager of the Sanquin Blood Supply Foundation.
The average score of the 2009 employee satisfaction survey
was 7.0 and this was only slightly below the national
index. Rob: Naturally, you start searching for solutions
enabling you to achieve most improvement.’
A number of project groups addressed the topics which
showed the most divergent results: cooperation, working
conditions (particularly the proper balance between work
and private life) and trust in the management. The search
for improvements resulted in a number of surprising
proposals. ‘We are in fact rather a conservative
organization’, Rob confirms. ‘This is why it was all the
more surprising that all suggestions were received so
enthusiastically. We have also tried all approaches on
the Executive Board and they were very pleased with
the solutions.’
This is how the World Café was introduced. The idea is to
invite interdisciplinary groups in an informal setting and
to ask them to respond to a number of thought-provoking
statements in a relaxed atmosphere. In the process of
discussion, you may be able to draw up a list of solutions.
‘We were allowed to serve as guinea pigs ourselves and
even though I was very sceptical, I must admit:
it is much more fun to talk when you’re sitting at a
table like that, making notes on the table cloth!
When the Executive Board reacted in the same way, we
decided to add this method to our management tools.’
Participation Another issue addressed by a working group concerned
working conditions. Particularly those who work in paid
employment considered the balance between work and
private life to be unsatisfactory. According to Rob, they
lack the possibility of determining their working hours
themselves. ‘This is why we are now doing a self-
rostering and shiftpicking pilot.’ Self-rostering means
that teams are allowed to determine their own roster by
consultation and may also arrange for any replacement
that may be necessary. Shiftpicking refers to pre-defined
services: a particular service may be chosen well in
advance. The idea is that people are given a greater say
in determining their working hours. The fact that they are
consulted in this is often a first step.
The survey showed that Sanquin had a fairly low score
with respect to the subject ‘Trust in Management’. ‘That
is difficult, of course: why don’t they have trust? It is
not easy to grasp anything as vague as that. But the
worst thing you can do is to stop talking about it at all’,
says Rob. We chose an instrument of FranklinCovey, the
training agency that is associated with the success author
Stephen Covey.
The idea is that the two of you play a card game with trust
cards. In this way the manager and the employee enter
into a discussion about a subject that is otherwise difficult
to grasp. ‘Of course, we know that there is no miracle
drug. We are not going to get a perfect ‘10’ score next
time. That would not be realistic. But we have taken
all results seriously and we have provided the directors
and managers with a set of tools they can use during
an evaluation. And in a few years’ time, we are going
to assess where we stand at that time.’
There is no miracle drug for a perfect ‘10 out of 10’ score
Personnel & Organization
‘We were allowed to serve as guinea pigs and I must admit: it’s much more fun talking in a café, taking notes on the table cloth!’
Personnel & Organization
20 | | 21
Workforce as at 31 Dec. 2010 (number of employees and number of fte)*
* excluding hiring and extra deployment of Sanquin’s own employees
In 2010 Sanquin had 7 employees (f) with a WAO benefit.
Permanent employment Temporary employment Total full-time / total part-time
Total workforce
Fulltime Parttime Fulltime Parttime Fulltime Parttime
Number FTE Number FTE Number FTE Number FTE Number FTE Number FTE Number FTE
2010 Male 626 630.95 177 106.60 115 115.90 43 10.00 741 746.85 220 116.60 961 863.45
2009 Male 592 595.80 169 99.11 117 117.77 58 25.64 709 713.57 227 124.75 936 838.32
2010 Female 349 349.94 1,346 754.22 88 88.28 193 89.45 437 438.22 1,539 843.67 1,976 1,281.89
2009 Female 332 332.80 1,351 725.66 93 93.00 180 105.07 425 425.80 1,531 830.73 1,956 1,256.53
2010 Total 975 980.89 1,523 860.82 203 204.18 236 99.45 1,178 1,185.07 1,759 960.27 2,937 2,145.34
2009 Total 924 928.60 1,520 824.77 210 210.77 238 130.71 1,134 1,139.37 1,758 955.48 2,892 2,094.85
Years of service structure (number of employees)
Number of
employees
New Loyal/known
m v total total
2010 2009
< 1 180 278 458 527
2-3 126 216 342 308
4-5 51 102 153 192
6-9 171 401 572 583
10-14 136 298 434 399
15-19 93 246 339 305
20-24 92 187 279 278
25-29 46 106 152 146
30-34 52 105 157 118
35 and over 14 37 51 36
Total 961 1,976 2,937 2,892
The average duration of Sanquin’s employees amounted to
11.65 years of service (10.87 in 2009).
the European Blood Bank Inspection Training (EUBIS).Together with Jan-Peter Jansen van Galen, he developed
A special training that was very popular with our bloodbank colleagues from the Eastern bloc countries.
Boudewijn Hinloopen (head of processing)
Personnel & Organization
22 | | 23
Sickness absenceThe sickness absence rate (excluding maternity leave) fell
slightly from 4.49% in 2009 to 4.39% in 2010. This meant
that for the second consecutive year, the rate was lower
than that of the entire healthcare sector (5.69%) and in
the hospital sector (4.55%).
(Sickness absence percentages inclusive and exclusive of
maternity leave)
Male Female Total
Incl. Excl. Incl. Excl.
2010 3,60 5,57 4,71 4,94 4,39
2009 3,96 5,70 4,73 5,14 4,49
The average duration of Sanquin’s employees was 11.65 years
of service (10.87 in 2009)
Comparison (2010)
Male Female Total
Incl. Excl. Incl. Excl.
Healthcare sector 4.58 7.68 5.98 7.04 5.69
Hospital sector 3.75 6.58 4.79 5.93 4.55
Duration of absence, inclusive & exclusive of maternity leave(in days)
Male Female Total
Incl. Excl. Incl. Excl.
2010 14,88 15,62 13,80 15,53 14,14
2009 11,41 15,00 13,00 13,89 12,50
Frequency of absence, inclusive & exclusive of maternity leave(number of reports)
Male Female Total
Incl. Excl. Incl. Excl.
2010 1,32 1,50 1,49 1,50 1,49
2009 1,47 1,61 1,57 1,56 1,54
Staff turnover; those leaving service in 2010 (number of employees)
2010 2009
career elsewhere 81 79
personal circumstances 24 11
working conditions 2 1
unfitness 0 4
unauthorized absence 0 0
urgent reason 2 0
reorganization 6 6
obu / flex / TOP / pension 40 29
termination of temporary employment 67 122
occupational disability 3 5
death 4 3
other* 34 68
Total 263 328
Age structure 2010
(number of employees)
Male Female Total
2010
Total
2009
0-24 32 54 86 112
25-34 205 336 541 522
35-44 255 505 760 762
45-54 291 669 960 956
55-59 110 278 388 368
60 and over 68 134 202 172
Total 961 1,976 2,937 2,892
Average age 43.77 45.06 44.63 44.23
* This concerns, for example, transfers within Sanquin and
dismissals during the trial period.
In 2010 the staff turnover rate dropped from 11.3% to 9.0%.
The most important reason for leaving Sanquin was a career
elsewhere. In addition, termination of temporary employment,
personal circumstances and (early) pension were important
reasons for leaving the organization in 2010. As in 2009, it was
generally easy to fill vacancies in 2010. At the end of 2010,
there were 26 vacancies that had not yet been filled,
the same number as in 2009.
Salary scale breakdown 2010
(number of employees)
Young workers pay scale Preliminary pay scale Graded pay scale Total
Male Female Male Female Male Female
5
10
15
20 4 16 20
25 1 1 1 79 61 143
30 4 6 13 51 254 328
35 1 1 122 689 813
40 1 115 159 275
45 7 7 119 253 386
50 81 131 212
55 2 87 66 155
60 1 91 121 213
65 38 26 64
70 19 10 29
75 17 15 32
80 9 1 10
other* 115 142 257
Total 4 7 10 25 947 1,944 2,937
* Concerns employees who receive a nominal salary; employees who are subject to a different salary scale system under the
‘transitional regulations for the Collective Agreement of Sanquin 2001’; and trainee research assistants who are subject to
the salary system of the UMCs.
Personnel & Organization
24 | | 25
association in Groningen for 26 years. Together with his Hans has been the driving force behind the staff
enthusiastic team, he forms a stable factor within Sanquin.
Hans Hoekstra (chairman of the staff association)
26 | | 27
In 2010, the Sanquin Blood Supply Foundation came
to the aid of hospitals and suppliers by providing them
with Vitamine D test results. ‘This is an operation
to be proud of’, says Ruben Baumgarten, director of
Diagnostic Services. Over the past year, hospitals and
other suppliers have faced serious problems when the
largest supplier of Vitamine D tests unexpectedly proved
unable to meet demands. The latter made an urgent
appeal to Sanquin to help out for the Dutch market.
Ruben immediately felt that this was a great challenge.
‘We have considerable know-how and experience and
in addition, we are an independent party. We are also
well-known for the quality of our services, excellent
logistical facilities and the pleasant manner in which
we communicate with customers.’
It did not take long for Sanquin to decide to come to the
aid of the customers within hospital labs. Almost immedi-
ately, Sanquin went all out to make this possible.
ComplimentNext, the Diagnostic Services people managed to have
the requested Vitamine D tests operational within a very
short period − approximately four to five weeks. ‘First and
foremost, thanks to a tour de force of our people, who
took great pains to ensure that the correct results were
supplied to the hospitals and suppliers without loss
of time. The determinations had to be at least as good
as those the customers were used to. It is great that
we managed to pull this off,’ says Ruben. The success of
this operation was also conditional upon the flexible
attitude adopted by the Executive Board, which allowed
investments in both equipment and human resources to
be made at very short notice. Ruben: ‘A compliment is
really deserved here.’
It is expected that this extra service will be continued until
the original supplier itself is able to supply the Vitamine D
test again.
Fast and adequate reactionProducts & Services
‘We have considerable know-how and experience. In addition, we are well-known for the quality of our services and the pleasant manner in which we communicate with customers.’ Tudor Schleurholts (donor physician based in Zwolle)
When there were a number of sick people and the situation was
critical, he was the ministering angel: thanks to his assistance,
we were back on schedule again.
Products & Services
28 | | 29
Since 2010, the Sanquin Blood Supply Foundation has
also been present at schools with two different teaching
packages, one for primary schools and one for secondary
schools.
In 2008, Sanquin was asked by Nefarma, the industry
organization for pharmaceutical companies, whether
Sanquin wanted to participate in the project called Ik van
binnen (‘Me Inside’) for group 8 of the primary school.
Sanquin agreed to do so. Next, cooperation started at the
beginning of 2010. Bloed en zo (‘Blood et cetera’) supple-
ments the existing teaching packages for the skeleton, the
nervous system and organs. Teachers received a film, sup-
ported by a website and materials, to be used in the class-
room. By now, more than 3,700 schools across the country
have started using the ‘Me Inside’ method. According to a
first survey, the method was appreciated very much: 77%
of the persons interviewed say that they use the teaching
package at least twice a week and 96% indicated that they
will use it in the future too.
Practical trainingBloed en afweer (‘Blood and immunity’) is another project
with which Sanquin builds knowledge within the educa-
tional system. Project leader Jan Willem Smeenk: ‘We’ve
had the idea of doing something at secondary schools
as well for some time now. Sanquin is well represented
at universities and polytechnics, but we were absent at
secondary schools.’ Because Sanquin considers informa-
tion provision to be a social responsibility, it developed a
biology pilot − the package called Bloed en afweer (‘Blood
and immunity’) − for the upper years of senior general
secondary education and pre-university education as early
as 2009. Even though both subjects were addressed in the
context of regular biology classes, the connection between
the two did not receive any attention.
Apart from blood, the topics addressed include transfusion,
immunity and rejection.
Pupils may participate in practical training in which
they determine blood groups, carry out coagulation
experiments and look at blood components under the
microscope, among other things. Jan Willem: ‘In the end,
we also intend to show how cool blood is; we want to
make people enthusiastic about science subjects and
show how interesting research can be.’ Apart from the
teaching package with the practical training, there is
a website. In addition, teachers may enrol for refresher
courses. Whether the project will be continued depends on
the interim evaluation.
From March to November of last year, the Sanquin Blood
Supply Foundation carried out extra tests on donors for the
presence of the Q fever bacterium. This was a precautio-
nary measure.
At the end of 2009, it seemed that a large Q fever epidemic
would break out in specific parts of the Netherlands.
Sanquin expected negative consequences for the blood
supply. With a number of hospitals, Sanquin developed a
test to screen donors for the presence of the Q fever bacte-
rium. Director of Diagnostic Services Ruben Baumgarten:
‘We have taken this measure because the bacterium
may be transmittable through the blood. In that case,
donors may infect someone through their blood. The
test we developed shows whether a person is infected,
even if the donors do not show any symptoms yet.’
Donors are always screened for infections in order to make
the blood supply as safe as possible. But because of the
imminent Q fever epidemic, all donors in the risk areas
in the province of Noord-Brabant underwent additional
screening for the presence of the Q fever bacterium from
March to November 2010.
Operation Screening donors for the Q fever bacterium in the risk
areas was a large-scale operation, on which Sanquin
spent a great deal of energy, time and money. ‘Not only
on the necessary equipment and the development and
validation of the test but also on the logistics required
to implement the test in the high infection risk areas.
That was really quite a job’, says Ruben. ‘But things
went very well and we can be very proud of that. In
doing so, Sanquin proves that it is able to respond to
unexpected situations in a flexible manner.’
When, in November 2010, the threat had ceased, we stopped
carrying out this test for the time being. Fortunately, not
a single donor was found to be infected with the Q fever
bacterium. Ruben: ‘The infrastructure for screening donors
for the Q fever bacterium is operational, however. If there
are any indications that an epidemic may break out
after all, we can resume the test procedure immediately.’
Large-scale Q fever operation Blood is cool
Joke Trompetter and Rob de Groot (post room)
For years Joke and Rob have been managing the post
room on the Plesmanlaan with great commitment.
Products & Services
30 | | 31
Their weekly tours for external groupsare regarded as a very valuable PR contribution.
Rachid Essinouh (l) (issue team leader) and Güner Durus (r) (processing assistant)
32 | | 33
In 2010 a new research department was established:
Haematopoiesis Research. Led by Marieke von Lindern,
this department will address a prime focus for scientific
research within the Sanquin Blood Supply Foundation
over the next few years: cellular therapy. The crux of
the research is to unravel and exercise influence on the
formation of the various types of blood and immune cells
(‘haematopoiesis’). Jan Willem Smeenk of the Research
Department puts it briefly: ‘How do you harvest cells;
how do you culture cells, and how does blood cell
formation work? This research group is perfectly in
line with our ambitions in the field of patient care.’ At
this point already, Sanquin is responsible for a substantial
proportion of the bone marrow transplantations carried
out in the Amsterdam region, namely the purification and
storage of bone marrow cells given to cancer patients after
the malignant cells have been removed. To improve this
type of cellular therapy, a great deal of research is needed,
for example, to examine whether cells may be manipulated
in such a way that they are better able to find their way
back into the bone marrow. Sanquin is also involved
in setting up closed culture systems for cellular therapies
of this kind.
Anaemia But the new research group has a broader scope. For
example, Marieke works on the unravelling of the forma-
tion of red blood cells. This is supposed to yield knowledge
about rare congenital types of anaemia. But also − which
is even more exciting − pave the way for the creation of a
blood substitute. ‘This is still in the future’, Jan Willem
emphasizes. ‘With the present state of technology, we
still need a sizable brewery to make one bag of blood.’
Even so, this shows promise. On a small scale, a blood
substitute could be a godsend for patients with so many
antibodies that they cannot tolerate donor blood. In the
end, the department is supposed to grow into a national
expertise centre for red blood cells. Other research lines
address the use of immune cells against cancer: immuno-
therapy, for example by inducing specific immune cells
(T cells) to launch an attack on tumour cells. This can
be done by isolating and culturing T cells aimed against
cancer cells. But also by manipulating other cells of the
immune system in such a way that, once back in the body,
they activate T cells capable of destroying cancer cells.
This latter strategy is being examined for a treatment of
esophageal cancer.
MergerThe Haematopoiesis Research Department is partly a
merger of existing groups within and outside Sanquin.
For example, Marieke, together with Emile van den Akker,
come from the Erasmus MC, and Martijn Nolte and
Monica Wolkers come from the AMC. Sanquin’s existing
stem cell lab, led by Carlijn Voermans, was included in
the department too. Yet, these parts constitute something
new. Jan Willem: ‘For the first time, the research was
deliberately structured for the purpose of supporting
our plans for services to hospitals.’
Towards a blood substituteResearch
‘With the present state of technology, you need a sizable brewery to make one bag of artificial blood.’
Research
34 | | 35
On 10 June 2010, the collaborating research teams of the
Netherlands Cancer Institute (NKI) and the Sanquin Blood
Supply Foundation won the Amsterdam Inventor Award.
The teams developed technologies that allow the faster
development of vaccines and immunotherapies for
preventing and treating infectious diseases and cancer.
The Award, an initiative taken by the Amsterdam Innova-
tion Motor, Avantium and the Economic Affairs Depart-
ment of the Municipality of Amsterdam, is regarded as
the prize for the most innovative invention of knowledge
institutes and companies in the region. Roel Melsert,
managing director of the business unit Reagents, is proud
of it. ‘The nice part of it is that entries originated not
only from the life sciences. Companies like Shell and
Tom Tom had also submitted innovations. It is a good
thing to compete with other lines of business.’ The jury
considered not only the scientific value of the inventions
but also their societal relevance and economic prospects.
The members were Prof. Pieter Drenth, former rector mag-
nificus of the Free University and former President of
the Royal Academy of Arts and Sciences; Adri Baan,
former member of the Executive Board of Philips, and
Pieter ter Kuile, managing director of Kempen and Co
Corporate Finance. Roel: ‘These are people with a huge
track record.’
Protection The research teams led by Prof. Ton Schumacher and
Dr Huib Ovaa (Netherlands Cancer Institute) and
Dr. Wim van Esch (Sanquin) looked at ‘T-killer cells’ as
they are known. These are important immune cells
that protect us against infection and specific types of
cancer. There are many millions of them in the human
body. Nearly every T-killer cell recognizes its own ‘enemy’,
being small protein fragments known as ‘epitopes’. These
epitopes are found on the outside of body cells, which
are infected with viruses, for example or which are the
result of cancer. If a T-killer cell recognizes an epitope,
it binds to the pathogenic cell and kills it.
T-killer cells against cancerFor years, scientists have been trying to influence this reac-
tion in such a way that T-killer cells may be used against
cancer or infections, for example by means of vaccines
or immunotherapy. The first successes have already been
achieved, but there are still quite a few obstacles on the
road. For example, it is by no means always easy to iden-
tify the protein fragment from a cancer cell or a virus that
induces an immune response. To use T-cells more effec-
tively, it is necessary to know epitopes and to describe the
T-cells. This is the very reason why the research groups of
the NKI and Sanquin Blood Supply Foundation developed
two innovative technologies: with an exchange technology
based on UV light, it is relatively easy to produce thou-
sands of different fluorescing complexes that allow inter-
esting T-killer cells to be made visible; the other technology
concerns a smart colour coding system. The combination
of these two technologies allows various groups of
T-killer cells to be identified in a blood sample relatively
fast and easily.
Slovenia had a problem with the screening equipment.Johan and his team screened the Slovenian blood
for their colleagues within 15 hours.
Johan IJlst (team leader of NAT screening SDI)
Sanquin wins prestigious innovation price
Research
36 | | 37
Dutch blood transfusions are safe. As a result of the strict
selection of donors and the application of costly and
advanced tests, the risk of the transmission of infections
is virtually non-existent in the Netherlands. ‘In the
Netherlands, donated blood is extremely safe’, says
Prof. Hans L. Zaaijer in his oration, delivered when he
accepted his professorship in Blood-borne Infections at
the Academic Medical Centre in Amsterdam.
Despite all efforts, there are limits to safety. On the one
hand, this is because the presence of the known pathogens
cannot be proved sometimes. On the other hand, this is
because time and again we will be facing new threats,
posed by factory farming, for example. And sometimes
there are no tried preventive measures for new infections,
according to Hans, who has been managing the research
department of Blood-borne Infections of the Sanquin Blood
Supply Foundation since 2008.
Rare The transmission of infectious diseases as a result of blood
transfusions in the Netherlands is extremely rare. Dutch
blood donors contract hepatitis B and C less often than the
rest of the population. But it cannot be ruled out com-
pletely. Infections that have existed for a longer time are
discovered with − cheap − tests, which detect antibodies
made by the body’s immune response. These tests do not
detect recent infection, however. There are more expensive
tests for that purpose, which directly prove the presence
of a virus. Every year, a few cases of hepatitis B, hepatitis
C and hiv are discovered as a result of that. These tests are
worth the money. Hans points out that decisions on the
safety of blood are not just based on cost-benefit analy-
ses. ‘Blood safety is not just number work. Emotions
play just as important a role. Emotions of the public
and patients, donors, but also of administrators and
politicians.’
Yet, there are limits to the expenses incurred in connection
with blood safety. A test against the unknown and usually
harmless HTLV virus was introduced, but the costs amount
to millions of euros per life year saved. At what price level
do we decide that a residual risk is acceptable?
New threats The concentration of animals and the administration
of substantial quantities of antibiotics in the Dutch bio-
industry give rise to new threats. On the one hand, these
are due to as recently unknown or insignificant pathogens,
such as prions, the Q fever bacterium and the hepatitis E
virus. On the other hand, these are due to already
well-known pathogens which have become resistant,
such as MRSA, VRE and, recently, the multi-resistant
E.coli bacterium, which causes urinary tract infections.
‘Reforms in intensive cattle breeding may reduce
these risks’, Hans concludes.
ever since communication with externalAs true pioneers they set up a new department;
contract partners has been running smoothly.
Mireille van Roden (l) and Theresa Guhr (r) (account managers of toll manufacturing)
New infections mean new risks
38 | | 39
The plasma products of the Sanquin Blood Supply
Foundation have to meet very strict requirements. Last
year, the business unit Pharmaceutical Services developed
a method for measuring prion particles, misfolded protein
particles with pathogenic features. Such as Creutzfeldt–
Jakob disease (mad-cow disease). In order to make blood
and plasma products as safe as possible, it is important
to know for certain that these do not contain any viruses
or prions. ‘There is not yet any test, however, that is
sensitive enough to demonstrate the presence of minute
quantities of prions’, says Peter van Mourik, who was
managing director of Pharmaceutical Services until the
end of 2010. The risks relating to blood transfusions can
be reduced only by excluding specific groups of donors.
In the production process of plasma products, there are
more possibilities, because in this case there is a larger
number of different process stages. Of one of the product
stages, a virus-removing technique by means of nano-
filtration, it has by now been proved that it can remove
prions as well. Peter: ‘To describe the prion-removing
capability of a product step, one should first have
a reliable test and material with a sufficiently high
concentration of prions. Last year we first managed to
develop this kind of validation method on the basis of
both these components.’
Safe The method for detecting prion removal comprises a num-
ber of steps. In a nutshell: prions are first multiplied until
high concentrations can be harvested. Next, they are put
in the starting material of the product stage to be studied.
This step is executed at the laboratory scale, after which
the Western-Blot test is applied to measure whether any
prions are left. Peter: ‘We have been able to optimize the
test to such an extent that we are able on a systematic
basis to obtain a positive test result even if the material
is diluted by a factor ten thousand. With this kind of
sensitivity we are able to effectively describe the safety
contribution of a product stage and that is important
to the Plasma Products division.’
Reaping the best possible benefitsUntil now, the division depended on a limited number of
European companies that were able to offer the validation
method under the quality system required. According to
Peter, the colleagues of the Plasma Products division are
no longer troubled by long waiting lists and they make
the best possible use of existing facilities at Pharmaceuti-
cal Services. ‘But we, too, reap the benefits of the new
development. Other companies have indicated
that they are interested in this method. In addition,
this may lead to new cooperation in other fields.’
In collaboration with Siemens Healthcare Diagnostics,
the Sanquin Blood Supply Foundation has developed
laboratory tests to improve the detection of a type of bone
marrow cancer.
It concerns a new test that makes it possible to detect the
free light chains kappa and lambda of immunoglobulins
in blood. ‘This is a milestone for Sanquin’, says Roel
Melsert, managing director of the Reagents Business Unit.
‘We worked on the development of this test for five
years.’ Sanquin produces the test-kits for Siemens. Next,
Siemens is responsible for their worldwide distribution
and sale. In December 2010, the kits were introduced in a
number of European countries, including the Netherlands.
During the final development stages, we cooperated with
the Clinical, Chemical and Haematological Laboratory
of the Jeroen Bosch Hospital in Den Bosch.
More reliable The test is designed for the bone marrow cancer called
‘multiple myeloma’, also known as ‘Kahler’s disease’.
The disease is the result of the uncontrolled growth of
plasma cells, immune cells that produce antibodies
(immunoglobulins). As a result of this uncontrolled
growth, loose particles of these immunoglobulins enter the
blood, including the ‘free light chains’ as they are called.
The new test detects these free light chains more easily
and in a more reliable and accurate manner than older
tests. This means that the presence of free light chains
can be proved even in the case of smaller quantities, and
that false alarms are less likely to occur. ‘These tests are
automated’, says Roel. ‘In addition, they are more
sensitive and more specific than the older tests.
Another advantage of the new test is that there are no
longer any differences between the production series
and that samples with extremely high concentrations
are no longer overlooked. The older tests did have these
problems’, says Roel.
For the hospital laboratories, the availability of these
new tests means that there will be a broader range of
diagnostics that can be offered. Doctors may detect and
track the disease faster. Multiple myeloma affects mainly
older people. In view of the ageing of the population,
an increase in the number of patients is to be expected.
The disease is often associated with bone pains caused
by the uncontrolled growth of plasma cells in the bone
marrow. Sometimes spontaneous bone fractures, anaemia
and reduced immunity occur. With the right treatment,
the disease can sometimes be controlled for years.
Test kit for bone marrow cancer Safe blood
Publications
As at 31 Dec. 2010
As at 31 Dec. 2009
Number of theses 11 10
Number of publications (peer reviewed)
131 122
Number of other publications 18 19
Research
40 | | 41
comes to looking for creative solutions. Pasquale is very inventive when it.
More than once he designed a useful program during the weekend.
Pasquale di Scala (head of donor administration of Blood Bank North West)..
42 | | 43
Sanquin’s mission statement reads as follows:
The Foundation works on a not for profit basis to provide blood supplies and to promote transfusion medicine in such a way as to meet the most stringent quality, safety and efficiency requirements. Sanquin provides products and services, carries out research and offers education.
Apart from Sanquin’s annual accounts prepared in
accordance with the relevant statutory regulations, this
report includes the consolidated financial results of CAF-
cvba in Brussels and Sanquin Oy in Helsinki. The CAF is
a Belgian plasma fractioning facility in which Sanquin
posesses a 50,01 percent interest since 2008. The Belgian
Red Cross and the French LFB own the other 49.99%
interest. Sanquin Oy is a small Finish subsidiary that
maintains contacts with Finish customers.
Report from the Executive Board
The Blood Supply Act intends to ensure the quality, safety and availability of blood and blood products in the Netherlands. Sanquin has embraced this objective.
Executive BoardIn 2010 the Executive Board consisted of:
T.J.F. Buunen PhD (chair)
H.J.C. de Wit D Pharm(deputy chair)
Prof. E. Briët MD PhD (until 1 August)
Prof. R.A.W. van Lier MD PhD (from 1 September)
Secretary: Ms H.M.H. de Bruijn-van Beek LLM
Due to his reaching retirement age, Prof. E. Briët resigned.
The vacancy was filled by Prof. R.A.W. van Lier.
Report from the Executive Board
44 | | 45
Ministery of Health, Welfare and SportIn 2010 frequent consultations were held at the Ministry of
Health, Welfare and Sport at both ministerial and civil ser-
vice level. Important subjects that were discussed included
the change in the donor input structure, the umbilical cord
blood bank, Sanquin’s role in the blood supply in Bonaire,
measures by Sanquin to make blood products safer and the
subsequent research started by the Ministry of Health, Wel-
fare and Sport on the efficiency of the organization’s public
section and the costs of plasma product supply by Sanquin.
Ministry of DefenseAs in preceding years, Sanquin maintained contact with the
Ministry of Defence about blood supply for the armed forces.
In the negotiations, the central question was how to intensify
cooperation between Sanquin and the Military Blood Bank.
European CooperationSanquin is represented in the European Blood Alliance
(EBA) and the International Plasma Fractionation Associa-
tion (IPFA). Jeroen de Wit, deputy chair of the Executive
Board, chairs the Executive Board of the EBA. Sanquin’s
employees cooperate with European colleagues in updating
the ‘Guide to the Preparation, Use and Quality Assurance
of Blood Components’of the Council of Europe.
Patient associationsSanquin maintains constructive contacts with a large number
of patient associations. These are the following associations:
National • Stichting AfweerStoornissen
• Nederlandse Vereniging van Hemofilie Patiënten
• Vereniging Spierziekten Nederland
• Patiënten vereniging voor Hereditair Angio Oedeem
en Quincke’s Oedeem
• ITP (Idiotypische Trombocytopenische Purpera)
• Patiëntenvereniging Nederland
• Stichting Zeldzame Bloedziekten
• Stichting StiKa (Ziekte van Kawasaki)
• Nederlandse Patiënten Consumenten Federatie
International• Patiënt Association for Hereditary AngioEdema
International
• European Haemophilia Consortium
• US HAE Association (HAEA)
• Thalassaemia International Federation
Users of blood products At regional level, there are user councils, in which represen-
tatives of hospitals and representatives of Sanquin have
a seat. Representatives of hospitals also have a seat
on the National Users Council (Landelijke Gebruikersraad),
which also rendered advice to the Executive Board on
logistics and services in 2010. Important discussion subjects
included the following: restriction on the use of O negative
red blood cells, transfusions outside hospitals, the availability
of pooled normal plasma, the use of the 18-digit barcode
on blood bags, the use of collection bags for red blood cell
preparations, the further typing of blood groups in donors
and plasticizers in plastic blood bags. Sanquin is represented
in both the Nederlandse Vereniging van Hemofiliebehande-
laars and the Interuniversitaire Werkgroep voor de Behandel-
ing van Immuundeficiënties.
continuity by having the screening laboratoryEd was the driving force behind ensuring
cooperate with the blood bank in Leuven.
Ed Bakker (head of laboratory of pre-analysis and virus serology SDI)
External contacts
46 | | 47
behind Sanquin’s fancy new website.The three of them are the driving force
Bert van den Berg (l) web master, Tjipke Schouten (m) coördinator digital media and Debbie van Rijk (r) (web editor)
48 | | 49
The Board met four times in 2010. During the meetings
the policy plan, the 2011 budget, the medium-term plans
and the 2012-2016 Strategy Paper were discussed, as well
as the financial reports, the annual accounts, and the
auditor’s report. The Supervisory Board established that
the budget submitted to the Ministry of Health, Welfare
and Sport for 2011 had been approved by the Minister
after some adjustments.
On 1 June the Board took note of the follow-up research
into the benchmark for prices of cellular blood products
launched by the Ministry of Health, Welfare and Sport
within Europe, which will specifically aim at the efficiency
of the organization’s public section and the costs of the
supply of plasma products by Sanquin.
The Board itself asked information about Sanquin’s activi-
ties in the field of umbilical cord blood, about the changes
in the donor input organization implemented in 2010, and
the reorganization of the management of the blood banks
(Quartslag). The plans for new premises (building Y) for
the Plasma Products and Research divisions were on the
Board’s agenda, too.
The Board learned of the measures taken by Sanquin to
guarantee the quality of the blood supply.
On 1 June the chair of the Supervisory Board talked to the
Works Council about the general course of affairs in the
organization. They also talked about the procedure relating
to the appointment of a new member of the Executive
Board in relation to the vacancy arisen by the departure of
Prof. E. Briët, who retired. At the request of the Ministry of
Health, Welfare and Sport, a delegation of the Supervisory
Board spoke with the Minister of Health, Welfare and Sport
Report from the Supervisory Board
The Board supervises the Executive Board’s policies and the general course of affairs at Sanquin. In this annual report, the Board gives an account of its activities undertaken in 2010. The Sanquin Corporate Governance Code, adopted by the Board, contains rules and codes of conduct for good governance, effective supervision and clear accountability.
Supervisory BoardIn 2010 the Supervisory Board consisted of:
J.H. Schraven (chair) LLM
Prof. L.J. Gunning-Schepers (until 1 September)
Prof. F.C. Breedveld (from 1 September)
Prof. B. Löwenberg
J.C.M. Schönfeld
M. van Rijn
Due to her appointment as chair of the Dutch Health
Council, Prof. L.J. Gunning-Schepers resigned. The vacancy
was filled by Prof. F.C. Breedveld.
Report from the Supervisory Board
50 | | 51
about the salary of the member of the Executive Board to
be appointed. Based on a profile drawn up in advance,
Prof. R.A.W. van Lier was appointed. His salary was deter-
mined on the basis of the code of the NVZT for administra-
tors in the healthcare sector.
As the summaries included in this annual report show, the
composition of the Board was such that the requirements of
expertise and experience as defined in the articles of associa-
tion were satisfied more than sufficiently. J. H. Schraven was
reappointed as a member, and as chairman at the same
time, for four years. Prof. L.J. Gunning-Schepers withdrew as
member of the Supervisory Board in view of her appointment
as Chair of the Health Council. Prof. F. C. Breedveld was
appointed as Ms Gunning-Schepers’s successor.
The Supervisory Board evaluated both its own opera-
tions and those of the Executive Board and it has estab-
lished that its members are sufficiently independent. The
decision-making procedure in the Supervisory Board is
designed in such a way as to avoid any conflict of interest.
The quality, safety and availability of blood products were
made possible in 2010 thanks to the tremendous commit-
ment and efforts of donors. The Supervisory Board is most
grateful to them and to all Sanquin’s employees for the
manner in which they have achieved Sanquin’s objectives.
Amsterdam, May 2011
Supervisory Board
Harrie Breuker (interim project manager)
He had the brillant idea to have the old Sanquin
stationery turned into something new at a
workplace for mentally handicapped persons.
Marian Terbeek-Walraven (donor assistant)
In addition to being a passionate employee,
Marian is a passionate artist, as is shown by the
painting she specially made for the new collection
centre in Roermond.
52 | | 53
Operating incomeIn 2010, the total operating revenues rose by € 26.1 million
in 2010 to € 379.3 million (+ 7%). The most important
developments regarding the operating income can be sum-
marised as follows:
– At the Blood Bank turnover decreased by € 1.9 million
(-/- 1%). With a price increase of 1.7% this is mainly
caused by a decrease of the sales of short shelf-life blood
products to the hospitals.
– Supplies of plasma products have resulted in an increase
of the turnover by € 20.4 million (+14%). This increase
can be attributed especially to the manufacture of
Cinryze™ for the American market.
– The turnover of diagnostic services for blood samples of
Dutch institutions for health care increased in 2010 by
€ 0.7 million (+4%) by extending the services combined
with a regular increase of the rates.
– The volume of research and development from
external subsidies and contract research increased
by € 0.5 million (+7%). The financing of a research
programme that is adequate for the organisation still
requires special attention.
– The sales volume of reagents increased in 2010 by
€ 1.0 million (+15%).
– The item ‘Change in stocks of finished products and
work in progress’ has been included under operating
income. In 2010 this item amounts to € 16.3 million
compared to € 12.3 million in 2009. This revenue item
is explained in particular by the increase of the balance
sheet item ‘Stocks’.
Operating expenses The operating expenses for non-recurring items
increased in 2010 by € 19.9 million to € 349.5 million
(+6%). The most important explanatory factors are:
– The costs of ‘Raw materials and consumables’
have risen by € 2.2 million (+2%), especially because
of the increased production of plasma products.
– The costs for wages, salaries, social security charges and
pension contributions increased in 2010 by € 8.1 million
(+6%). The most important cause is the increase of the
workforce (+ € 2.7 million) in line with the increase
in turnover. In conformity with the Sanquin 2009-
2011 Collective Labour Agreement the salaries have
been increased (+ € 3.7 million) and the social security
charges and pension contributions have been raised
(+ € 1.7 million).
– The depreciation of tangible fixed assets has increased
by € 2.0 million (+11%) in line with the higher
investment level and the associated higher depreciation
charges.
– The other operating costs increased by € 7.7 million
(+8%). Most important cause of this is the increase of
the costs of maintenance of buildings and equipment,
partly in line with the increased contract production.
Result The increase of the operating income, combined with
a relative decrease of the costs, results in a strong
improvement of the operating result for non-recurring
items to € 29.8 million (+26%). The most important
cause of this was the increase of the contract production,
e.g. for Cinryze™.
Financial results and financial position
As a complete newcomershe set up a new fixed location
for the mobile blood bank.
Mariëlle Booi (teamleader Donor Affairs)
Financial Results and Financial Position
54 | | 55
In 2009 a non-recurring item of € 19.8 million was
accounted for in the result as a consequence of the release
of the Busquin tax liabilities in Belgium. In 2010 this still
led to a subsequent payment of € 0.4 million.
Interest charges of € 0.1 million were realised in 2010
(2009: interest income of € 0.7 million). Non-recurrent
income of € 0.1 million was also realised in the sale of
CAF-DCF shares (2009: € 1.9 million) based on an update
of the sales price received in 2008 as a consequence of the
release of the Busquin tax liabilities.
Moreover, in 2010 a non-recurring book profit of € 1.4 million
was realised in respect of the sale of a property in Leiden.
In 2010 the item Taxes has a negative influence of
€ 1.0 million on the result. In 2009 the tax burden
of € 7.0 million was almost completely caused by the
release of the Busquin tax liabilities in Belgium.
The Share of third parties of -/- € 1.4 million has been
included to correct the consolidated result of Sanquin, in
which CAF has been included for 100%, for the minority
interest in CAF which is not in the hands of Sanquin.
The operating result, combined with the above-mentioned
financial income and expenditure, non-recurring items
and taxes, leads to a net result of € 29.3 million, compared
with € 32.4 million in 2009.
Financial Results and Financial Position
The specification of the increase of the result before non-recurring items and tax is as follows:
(* € 1,000)
Increase of total operating income 26,098
Increase of raw materials and consumables -/- 2,151
Increase in salaries and social security charges -/- 8,063
Increase of depreciation -/- 1,993
Increase of other regular operating costs -/- 7,655
Increase in total operating expenses -/- 19,862
Increase of operating result before non-recurring items 6,236
Financial positionAs a consequence of the positive results in 2010 the financial position and the liquidity of the Foundation have improved.
Sanquin’s operating capital can be specified as follows:
(* € 1,000) 31 Dec. 2010 31 Dec. 2009
Liquid assets 88,256 70,537
Short-term receivables:
Trade accounts receivable 55,719 50,103
Other receivables 9,513 8,668
Stocks 104,859 92,770
Short-term debt:
Trade accounts payable and personnel liabilities -/- 47,866 -/- 42,525
Other short-term debts -/- 22,129 -/- 20,261
Operating capital 188,352 159,292
In particular because of the increase of the activities in the Plasma Products division, the operating capital of the
Foundation has increased by € 29.1 million to € 188.4 million.
Investments in tangible fixed assets are preferably financed with resources that are available to the Foundation in
the long term. The specification below shows that this has been realised:
(* € 1,000) 31 Dec. 2010 31 Dec. 2009
Tangible fixed assets 133,749 130,970
Financing with long-term resources 322,101 290,262
The financing with long-term resources can be specified as follows:
(* € 1,000) 31 Dec. 2010 31 Dec. 2009
Group capital 281,594 250,914
Provisions 9,953 10,537
Long-term debt 30,554 28,811
Financing with long-term resources 322,101 290,262
From the balance sheet it can be deduced that the solvability of Sanquin (Group capital / Total capital) has increased from
71% in 2009 to 72% in 2010.
56 | | 57Financial Results and Financial Position
Consolidated balance sheet as at 31 December 2010 (before profit appropriation)
31 Dec. 2010 31 Dec. 2009 (* € 1,000)
€ € € €
Assets
Fixed assets
Tangible fixed assets 133,749 130,970
Financial fixed assets 0 0
133,749 130,970
Current assets
Stocks 104,859 92,770
Receivables 65,232 58,771
Liquid assets 88,256 70,537
258,347 222,078
392,096 353,048
Liabilities
Group capital
Equity 262,834 233,518
Share of third parties 18,760 17,396
281,594 250,914
Provisions 9,953 10,537
Long-term debt 30,554 28,811
Short-term debt 69,995 62,786
392,096 353,048
Consolidated income statement for 2010
2010 2009
(* € 1,000)
€ € € €
Net turnover 356,971 336,247
Change in stocks of finished products and work in progress 16,300 12,303
Other operating income 6,032 4,655
Total operating income 379,303 353,205
Costs of raw materials and consumables 92,726 90,575
Wages and salaries 111,654 105,746
Social security charges including pensions 23,440 21,285
Depreciation of tangible fixed assets 20,003 18,010
Other operating costs 101,633 93,978
Total operating expenses before non-recurring items 349,456 329,594
Operating result before non-recurring items 29,847 23,611
Release of Busquin tax liabilities 424 19,794
Operating result 30,271 43,405
Proceeds from tangible fixed assets 1,373 0
Proceeds from financial fixed assets 133 1,893
Interest income 3,161 3,594
Interest charges - 3,291 - 2,917
Result from ordinary business operations before tax 31,647 45,975
Taxes on result from ordinary business operations - 966 - 6,979
Share of third parties - 1,365 - 6,561
Profit (loss) after tax 29,316 32,435
58 | | 59
Media expert with infinite patience; he is alwaysready to provide information and advice for a good interview
or a successful radio conversation.
Edward Przespolewski (doctor at Clinical Consultancy unit)
To: the Executive Board of Sanquin Blood
Supply Foundation
The accompanying abbreviated financial statements,
as included on page 53 up and to 57 of this report, which
comprise the consolidated balance sheet as at 31 December
2010, the consolidated income statement for the year then
ended, and related notes, are derived from the audited
financial statements of Stichting Sanquin Bloedvoorziening
(Sanquin Blood Supply Foundation) for the year ended
31 December 2010. We expressed an unqualified audit
opinion on those financial statements in our report
dated May 12, 2011. Those financial statements, and
the abbreviated financial statements, do not reflect the
effects of events that occurred subsequent to the date of
our report on those financial statements.
The abbreviated financial statements do not contain all
the disclosures required by Part 9 of Book 2 of the Dutch
Civil Code. Reading the abbreviated financial statements,
therefore, is not a substitute for reading the audited
financial statements of Sanquin Blood Supply Foundation.
Executive Board’s responsibilityThe Executive Board is responsible for the preparation
of the abbreviated financial statements in accordance
with the accounting policies as applied in the 2010
financial statements of Sanquin Blood Supply Foundation.
Auditor’s responsibilityOur responsibility is to express an opinion on the abbrevi-
ated financial statements based on our procedures, which
were conducted in accordance with Dutch Law, including
the Dutch Standard on Auditing 810 “Engagements to
report on summary financial statements”.
OpinionIn our opinion, the abbreviated financial statements
derived from the audited financial statements of
Sanquin Blood Supply Foundation for the year ended
31 December 2010 are consistent, in all material respects,
with those financial statements.
PricewaterhouseCoopers Accountants N.V.
Amsterdam, May 12, 2011
drs. N.J. van der Wal RA
Independent auditor’s report
62 |
Credits
PublicationSanquin Blood Supply FoundationAmsterdam, june 2011
Communication & Public Relations DepartmentPlesmanlaan 1251066 CX Amsterdam+31 202 512 30 00
Concept & realisationZB Communicatie & Media bv (www.zbcom.nl)
DesignZB/Janita Sassen, studio DIN
TextSanquin, ZB
PhotographyHarmen de Jong (www.harmendejong.nl)
PrintModderkolk Grafische Projecten
The information contained in this annual report has been collected with great care. No rights can be derived from this publication.
The Sanquin Blood Supply Foundation respects the fundamental principles of the International Red Cross.
Sanquin Blood Supply Foundation P.O. Box 98921006 AN AmsterdamThe NederlandsPhone: +31 20 512 30 00Fax: +31 202 512 33 03www.sanquin.nl
Executive Board Dr. T.J.F. Buunen (1949)
Main position:
– Chair of the Executive Board of Sanquin.
Other positions:
– Chair of the Supervisory Board of
Sanquin Oy in Helsinki
– (consolidated in Sanquin’s annual accounts)
– Chair of the Executive Board of CAF in Brussels
– (consolidated in Sanquin’s annual accounts)
– Board member of the International Plasma
Fractionation Association
– Delegated supervisory director of Euroclone b.v.
in Amsterdam
– (consolidated in Sanquin’s annual accounts)
– Director of Landsteiner Foundation for
Blood Transfusion Research
– Treasurer of the Board of Stichting Medisch
Centrum Slotervaart
– Treasurer of Stichting Joghem van Loghem
– Chair of the Supervisory Board of
Bevolkingsonderzoek Midden-West
H.J.C, de Wit (1953)
Main position:
– Deputy Chair of the Executive Board of Sanquin.
Other positions:
– Chair of the Executive Board of the
European Blood Alliance;
– Member of the executive board of the Committee
of Experts on Blood Transfusion of the EDQM
(European Directorate on the Quality of Medicines)
of the Council of Europe;
– Board member of Stichting IDTM;
– Board member of Stichting Tekke Huizinga Fonds;
– Member of the Medcial Ethics Committee of the LUMC
(until November 2010)
Prof. E. Briët (1945)
Main position:
– Member of the Executive Board of Sanquin
until 1 August 2010
Other positions:
– Professor of internal medicine at AMC-UvA;
– Professor of epidemiology of the blood transfusion
LUMC-UL;
– Member of the Netherlands Health Council;
– Chair of the Supervisory Board of Stichting IKA
– Vice-chair of the committee for evaluation of legislation
and vice-chair of the committee for innovative
prevention research, ZonMw;
– Board member of Stichting Haemophilia
Prof. R. A. W. van Lier (1956)
Main position:
– Member of Executive Board of Sanquin
from 1 September 2010
Other positions:
– Professor of experimental immunology at AMC-UvA;
– Board member of Stichting Immunovalley
– Chair of the Netherlands Society for Immunology
– Member of the Council of the ‘International Union of
Immunological Societies’
– Secretary of the scientific advisory council of
MS Research
– Member of scientific advisory council of the
Dutch Astma Fonds
– Member of scientific advisory council of the Landsteiner
Foundation for Blood Transfusion Research
60 | | 61
Supervisory Board J.H. van Schraven, LLM (1942)
Chair from May 2006 appointed in May 2006,
due to resign in May 2014, not eligible for reappointment
Main position:
–– Supervisory–Board–Chair–of–Tata–Steel–Nederland–B.V.–
and–non-executive–director–of–Tata–Steel–Limited–(India).
Other positions:
–– Chair–of–the–Board–of––
the–Netherlands–Standardization–Institute;
–– Member–of–the–Board–of–the–Carnegie–Foundation;
–– Chair–of–the–Board–of–the––
International–Longevity–Centre/Zorg–voor–Later;
–– Chair–of–the–Board–of–SEO–Economisch–Onderzoek
–– Member–of–the–Supervisory–Board–of–Stork–B.V.,––
NUON–Energy–B.V,–and–BNP–Paribas–OBAM–N.V.
Prof. L.J. Gunning-Schepers (Ms) (1951)
appointed in March 2005, due to resign in September 2010.
Main position:
–– Chair–of–the–Executive–Board–of–the–AMC––
until–September–2010.
Other positions:
–– Member–of–the–Supervisory–Board–of–DSM
–– Member–of–the–Supervisory–Board–of–Arbo–Unie
–– Member–of–the–Supervisory–Board–of–the–Rijksakademie–
voor–Beeldende–Kunsten–(Royal–Academy–of–Visual–Arts)
–– Chair–of–the–NFU
–– Conference–Concertgebouw
–– Member–of–the–Advisory–Council–of–the–Nieuwe–Kerk
M.J. van Rijn (1956)
Appointed in May 2008, due to resign in May 2012,
eligible for re-appointment.
Main position:
–– Chair–of–the–Executive–Board–of–PGGM;
Other positions:
–– Member–of–the–Supervisory–Board–of–Rijnland–Zorggroep
–– Member–of–advisory–council–of–the––
Dutch–Healthcare–Authority–
–– Chair–of–the–Supervisory–Board–of–Cardea
–– Chair–of–the–Supervisory–Board–of–Espria
–– Member–of–the–Board–of–Stichting–Steun–Alzheimercentrum
J.C.M. Schönfeld (1949)
Appointed in October 2003, due to resign in October 2011,
not eligible for reappointment.
Other positions:
–– Member–of–the–Supervisory–Board–of–Arcadis–N.V.
–– Member–of–the–Supervisory–Board–of–Draka–Holding–N.V.
–– Member–of–the–Supervisory–Board–of–S&B–Industrial–
Minerals–S.A.–Athens,–Greece
–– Member–of–the–Supervisory–Board–of––
Delft–University–of–Technology–
–– Member–of–Supervisory–Board–of–the––
Royal–Academy–of–Art–(Hogeschool–van––
Beeldende–Kunsten,–Muziek–en–Dans),–The–Hague–
–– Board–member–of–the–Dutch–Association–of–Listed–
Companies–(Vereniging–Effectenuitgevende–
Ondernemingen–-–VEUO)
–– Member–of–AFM–committee–on–Financial–Reporting
Other positions held by Members of the Supervisory Board and the Executive Board The–list–below–includes–the–most–important–other–positions–held–by–Supervisory–and–Executive–Board–members.
Annex
Prof. B. Löwenberg (1946)
Appointed in May 2005, due to resign in May 2013,
not eligible for reappointment
Main position:
–– Professor–of–Hematology–and–department–head––
at–Erasmus–MC–Rotterdam.
Other positions:
–– Member–of–the–Royal–Netherlands–Academy–of–Arts–
and–Sciences–(Koninklijke–Nederlandse–Akademie–van–
Wetenschappen–or–KNAW);
–– Board–member–of–Vereniging–Nederlands––
Tijdschrift–voor–Geneeskunde;
–– Scientific–director–of–Skyline–Diagnostics–B.V.
–– Member–of–the–Netherlands–Health–Council–
–– Member–of–the–International–Scientific–Advisory–Council,–
Lund–Strategie–Center–for–Stem–Cell–Biology–and––
Cell–Therapy–Lund–University,–Sweden
–– Member–of–External–Scientific–Advisory–Board–
Tumorzentrum–Ludwig–Heilmeyer-Comprehensive–
Cancer–Center,–Freiburg
–– Member–of–International–Scientific–Advisory–Board,
–– Department–of–Biomedicine,–Basel–University–
–– Chair–of–International–Science–Committee,
–– European–School–of–Hematology,–Paris
Prof. F. C. Breedveld (1950)
Appointed in September 2010, due to resign in
September 2014, eligible for reappointment
Main position:
–– Chair–of–the–Executive–Board–of–Leids–Universitair–
Medisch–Centrum–
Other positions:
–– Chair–of–Stichting–Curium
–– Chair–of–Stichting–Trombosedienst–Leiden–and–environs
–– Chair–of–Stichting–Houdster–van–Aandelen–Medipark–B.V.
–– Member–of–the–Board–of–Stichting–Leiden–Life–meets–Science
–– Member–of–the–Supervisory–Board–of–Leiden-Amsterdam–
Centre–for–Drug–Research–(LACDR)
–– Member–of–General–Board–of–Leids–Universiteits–Fonds
–– Member–of–the–Board–of–the–Bontius–Stichting
–– Chair–of–the–Supervisory–Board–of––
Stichting–Ipse–de–Bruggen
Annex
62 |
Credits
PublicationSanquin Blood Supply FoundationAmsterdam, june 2011
Communication & Public Relations DepartmentPlesmanlaan 1251066 CX Amsterdam+31 202 512 30 00
Concept & realisationZB Communicatie & Media bv (www.zbcom.nl)
DesignZB/Janita Sassen, studio DIN
TextSanquin, ZB
PhotographyHarmen de Jong (www.harmendejong.nl)
PrintModderkolk Grafische Projecten
The information contained in this annual report has been collected with great care. No rights can be derived from this publication.
The Sanquin Blood Supply Foundation respects the fundamental principles of the International Red Cross.
Sanquin Blood Supply Foundation P.O. Box 98921006 AN AmsterdamThe NederlandsPhone: +31 20 512 30 00Fax: +31 202 512 33 03www.sanquin.nl
Executive Board Dr. T.J.F. Buunen (1949)
Main position:
– Chair of the Executive Board of Sanquin.
Other positions:
– Chair of the Supervisory Board of
Sanquin Oy in Helsinki
– (consolidated in Sanquin’s annual accounts)
– Chair of the Executive Board of CAF in Brussels
– (consolidated in Sanquin’s annual accounts)
– Board member of the International Plasma
Fractionation Association
– Delegated supervisory director of Euroclone b.v.
in Amsterdam
– (consolidated in Sanquin’s annual accounts)
– Director of Landsteiner Foundation for
Blood Transfusion Research
– Treasurer of the Board of Stichting Medisch
Centrum Slotervaart
– Treasurer of Stichting Joghem van Loghem
– Chair of the Supervisory Board of
Bevolkingsonderzoek Midden-West
H.J.C. de Wit (1953)
Main position:
– Deputy Chair of the Executive Board of Sanquin.
Other positions:
– Chair of the Executive Board of the
European Blood Alliance;
– Member of the executive board of the Committee
of Experts on Blood Transfusion of the EDQM
(European Directorate on the Quality of Medicines)
of the Council of Europe;
– Board member of Stichting IDTM;
– Board member of Stichting Tekke Huizinga Fonds;
– Member of the Medcial Ethics Committee of the LUMC
(until November 2010)
Prof. E. Briët (1945)
Main position:
– Member of the Executive Board of Sanquin
until 1 August 2010
Other positions:
– Professor of internal medicine at AMC-UvA;
– Professor of epidemiology of the blood transfusion
LUMC-UL;
– Member of the Netherlands Health Council;
– Chair of the Supervisory Board of Stichting IKA
– Vice-chair of the committee for evaluation of legislation
and vice-chair of the committee for innovative
prevention research, ZonMw;
– Board member of Stichting Haemophilia
Prof. R.A.W. van Lier (1956)
Main position:
– Member of Executive Board of Sanquin
from 1 September 2010
Other positions:
– Professor of experimental immunology at AMC-UvA;
– Board member of Stichting Immunovalley
– Chair of the Netherlands Society for Immunology
– Member of the Council of the ‘International Union of
Immunological Societies’
– Secretary of the scientific advisory council of
MS Research
– Member of scientific advisory council of the
Dutch Astma Fonds
– Member of scientific advisory council of the Landsteiner
Foundation for Blood Transfusion Research
Sanquin Blood SupplyP.O. Box 98921006 AN AmsterdamThe NetherlandsPhone: (+31) 20 512 3000Fax: (+31) 20 512 3303
www.sanquin.nl
